Wang Li, Liu Hong-Rui, Liu Hui-Qi, Li Xi-Sheng, Tang Ting-Ting, Wang Kai-Jia, Wei Guang-Rong, Tian Jing, Zhang Yi-Yue, Luo Xiu-Ju
Department of Laboratory Medicine, The Third Xiangya Hospital of Central South University, Changsha 410013, China.
Department of Clinical Pharmacy, Hunan University of Medicine General Hospital, Huaihua 418000, China.
Life Sci. 2025 Jul 1;372:123625. doi: 10.1016/j.lfs.2025.123625. Epub 2025 Apr 12.
This study investigates the role of SET domain containing 1B (SETD1B), a histone lysine methyltransferase, in promoting ferroptosis induced by ischemic stroke through the upregulation of transferrin receptor 1 (TfR1).
An ischemic stroke model was established in C57BL/6J mice by subjecting them to 1 h of ischemia followed by 24 h of reperfusion. Brain damage was assessed by neurological impairment and infarct volume. Levels of SETD1B, TfR1, total iron, Fe, lipid peroxidation (LPO), ferritin (FPN), and GPX4 were measured. In vitro, HT22 cells were subjected to 14 h of oxygen-glucose deprivation (OGD) followed by 24 h of reoxygenation. SETD1B knockdown was performed to assess its impact on ferroptosis.
In the ischemic stroke mice, SETD1B expression was elevated, accompanied by increased ferroptosis markers, including higher levels of TfR1, total iron, Fe, and LPO, as well as reduced levels of FPN and GPX4. These phenomena were observed in cultured HT22 cells under OGD/R conditions. SETD1B knockdown effectively reversed these effects, decreasing ferroptosis markers and reducing Tfrc expression via preventing H3K4me3 enrichment at the Tfrc promoter.
These findings suggest that SETD1B enhances ferroptosis in stroke brain cells by a mechanism involving boosting H3K4me3 enrichment at the Tfrc promoter and subsequent upregulation of the expression of Tfrc. Targeting SETD1B may provide a therapeutic strategy for mitigating ferroptosis in stroke.
本研究探讨组蛋白赖氨酸甲基转移酶含SET结构域1B(SETD1B)通过上调转铁蛋白受体1(TfR1)在促进缺血性脑卒中诱导的铁死亡中的作用。
通过对C57BL/6J小鼠进行1小时缺血后再灌注24小时建立缺血性脑卒中模型。通过神经功能缺损和梗死体积评估脑损伤。检测SETD1B、TfR1、总铁、铁、脂质过氧化(LPO)、铁蛋白(FPN)和谷胱甘肽过氧化物酶4(GPX4)的水平。在体外,将HT22细胞进行14小时氧糖剥夺(OGD)后再复氧24小时。进行SETD1B敲低以评估其对铁死亡的影响。
在缺血性脑卒中小鼠中,SETD1B表达升高,同时铁死亡标志物增加,包括TfR1、总铁、铁和LPO水平升高,以及FPN和GPX4水平降低。在OGD/R条件下培养的HT22细胞中也观察到了这些现象。SETD1B敲低有效地逆转了这些效应,通过阻止H3K4me3在Tfrc启动子处富集来降低铁死亡标志物并减少Tfrc表达。
这些发现表明,SETD1B通过增强Tfrc启动子处的H3K4me3富集以及随后上调Tfrc表达的机制来增强脑卒中脑细胞中的铁死亡。靶向SETD1B可能为减轻脑卒中中的铁死亡提供一种治疗策略。